Company’s 36-month beta value is 0.66.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RNAZ is 17.24M, and currently, short sellers hold a 7.08% ratio of that floaft. The average trading volume of RNAZ on November 07, 2024 was 1.70M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RNAZ) stock’s latest price update
The stock price of TransCode Therapeutics Inc (NASDAQ: RNAZ) has dropped by -7.46 compared to previous close of 0.51. Despite this, the company has seen a fall of -6.94% in its stock price over the last five trading days. globenewswire.com reported 2024-11-05 that BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel before which TransCode appeared on October 1, 2024, has determined to grant TransCode’s request to continue its listing on The Nasdaq Stock Market subject to certain conditions to regain compliance. The Panel has also issued a Public Reprimand Letter in accordance with Listing Rule 5815(c)(1)(D).
RNAZ’s Market Performance
RNAZ’s stock has fallen by -6.94% in the past week, with a monthly drop of -2.76% and a quarterly rise of 81.50%. The volatility ratio for the week is 9.91% while the volatility levels for the last 30 days are 14.64% for TransCode Therapeutics Inc The simple moving average for the past 20 days is -21.76% for RNAZ’s stock, with a -31.03% simple moving average for the past 200 days.
RNAZ Trading at -1.02% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.59% of loss for the given period.
Volatility was left at 14.64%, however, over the last 30 days, the volatility rate increased by 9.91%, as shares sank -13.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +69.93% upper at present.
During the last 5 trading sessions, RNAZ fell by -6.94%, which changed the moving average for the period of 200-days by -40.29% in comparison to the 20-day moving average, which settled at $0.5997. In addition, TransCode Therapeutics Inc saw -92.89% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNAZ
Current profitability levels for the company are sitting at:
- -23.67 for the present operating margin
- 0.25 for the gross margin
The net margin for TransCode Therapeutics Inc stands at -23.77. The total capital return value is set at -13.48. Equity return is now at value -1048.70, with -334.48 for asset returns.
Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -67.97. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -351.8.
Currently, EBITDA for the company is -18.9 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 6.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
In a nutshell, TransCode Therapeutics Inc (RNAZ) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
